Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- GPS +23.9%, AMBA +20%, ZS +15.5%, ASAN +12.3%, GCO +9%, ESTC +7.9%, ULTA +7.7%, PD +6.9% (also authorized $100 mln for repurchases), COO +3.3%, IBTA +2.1%, PHR +2%, NTAP +1.6%
Other news:
- QSI +12.2% (CEO to serve as independent Chairman)
- VFC +5.4% (appoints new President of Vans)
- LRMR +4.1% (FDA selected to participated in START program)
- MLAB +3.2% (delayed earnings release - working to finalize our year end audit which is focused on finalizing the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to our Clinical Genomics and Biopharmaceutical Development divisions and the purchase accounting associated with the acquisition of GKE)
- BPMC +3.1% (announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT/AYVAKYT)
- VERV +2.7% (announces leadership update)
- JSPR +1.6% (to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024)
- NVS +1.3% (reports Phase III data confirming sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria)
- IONS +1.2% (presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema)